Top in cardiology: Vaccine-related myocarditis in young people, diet and CVD risk
Click Here to Manage Email Alerts
In the top story in cardiology last week, researchers reported that most suspected cases of COVID-19 vaccine-related myocarditis were mild and resolved quickly in patients aged younger than 21 years.
The researchers also noted the symptoms started a median of 2 days after vaccination, and the condition was more likely to affect white males.
Another top story was about a study that showed a significant association between higher quality diet and a composite outcome of CVD incidence, which included coronary heart disease, stroke, heart failure and CVD death, in patients who were classified as normal weight or overweight. However, the same findings were not observed in patients with obesity.
Read these and other top stories in cardiology below:
Symptoms of vaccine-related myocarditis in young people rare, mild, resolve quickly
Most young people under the age of 21 years with suspected myocarditis following COVID-19 vaccination had mild symptoms that resolved quickly, according to data published in Circulation. Read more.
Higher diet quality associated with lower CVD risk in adults with normal, overweight BMI
Higher diet quality was associated with lower risk for incident CVD in U.S. adults with normal weight and overweight, but not in those with obesity, researchers reported in the American Journal of Preventive Cardiology. Read more.
Exposure to certain toxic metals linked to development of subclinical atherosclerosis
Exposure to toxic metals, including arsenic, cadmium and titanium, among employees at a car assembly plant was linked to subclinical level of atherosclerosis in three vascular territories, researchers reported. Read more.
Blood pressure levels in US adults rose during COVID-19 pandemic
BP levels in U.S. adults increased during the COVID-19 pandemic compared with prior years, a finding that is not attributable to weight gain during lockdown, researchers reported in Circulation. Read more.
Addition of P2Y12 inhibitor fails to benefit noncritically ill patients with COVID-19
In a cohort of noncritically ill patients with COVID-19, the addition of a P2Y12 inhibitor to anticoagulation did not extend survival or lessen disease severity, according to results of the ACTIV-4a trial. Read more.